Insider Trading Alert - BDN, MRCY And BCRX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 19, 2015, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,088.06 to $96,569,200.00.

Highlighted Stocks Traded by Insiders:

Brandywine Realty (BDN) - FREE Research Report

Johnstone George, who is Executive Vice President at Brandywine Realty, sold 28,975 shares at $14.59 on May 19, 2015. Following this transaction, the Executive Vice President owned 108,008 shares meaning that the stake was reduced by 21.15% with the 28,975-share transaction.

The shares most recently traded at $14.58, down $0.01, or 0.08% since the insider transaction. Historical insider transactions for Brandywine Realty go as follows:

  • 4-Week # shares sold: 30,000
  • 12-Week # shares sold: 95,000
  • 24-Week # shares sold: 165,000

The average volume for Brandywine Realty has been 1.4 million shares per day over the past 30 days. Brandywine Realty has a market cap of $2.6 billion and is part of the financial sector and real estate industry. Shares are down 9.07% year-to-date as of the close of trading on Tuesday.

Brandywine Realty Trust is a publically owned real estate investment trust. The firm invests in real estate markets of the United States. It makes investments in office, mixed-use, and industrial properties. The stock currently has a dividend yield of 4.1%. The company has a P/E ratio of 244.0. Currently, there are 7 analysts who rate Brandywine Realty a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BDN - FREE

TheStreet Quant Ratings rates Brandywine Realty as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, disappointing return on equity and poor profit margins. Get the full Brandywine Realty Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Mercury Systems (MRCY) - FREE Research Report

Speicher Charles A, who is VP, Controller, and CAO at Mercury Systems, sold 322 shares at $14.00 on May 19, 2015. Following this transaction, the VP, Controller, and CAO owned 49,823 shares meaning that the stake was reduced by 0.64% with the 322-share transaction.

The shares most recently traded at $14.01, up $0.01, or 0.07% since the insider transaction. Historical insider transactions for Mercury Systems go as follows:

  • 4-Week # shares bought: 7,500
  • 4-Week # shares sold: 8,200
  • 12-Week # shares bought: 7,500
  • 12-Week # shares sold: 8,200
  • 24-Week # shares bought: 7,500
  • 24-Week # shares sold: 8,200

The average volume for Mercury Systems has been 119,200 shares per day over the past 30 days. Mercury Systems has a market cap of $492.1 million and is part of the technology sector and computer hardware industry. Shares are up 1.01% year-to-date as of the close of trading on Tuesday.

Mercury Systems, Inc. provides open sensor processing systems and services. The company operates through two segments, Mercury Commercial Electronics (MCE) and Mercury Defense Systems (MDS). The company has a P/E ratio of 62.6. Currently, there are 3 analysts who rate Mercury Systems a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MRCY - FREE

TheStreet Quant Ratings rates Mercury Systems as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Mercury Systems Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biocryst Pharmaceuticals (BCRX) - FREE Research Report

Staab Thomas R Ii, who is Senior Vice President and CFO at Biocryst Pharmaceuticals, sold 3,000 shares at $11.00 on May 19, 2015. Following this transaction, the Senior Vice President and CFO owned 162,144 shares meaning that the stake was reduced by 1.82% with the 3,000-share transaction.

The shares most recently traded at $11.28, up $0.28, or 2.48% since the insider transaction. Historical insider transactions for Biocryst Pharmaceuticals go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 12,105
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 60,000
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 116,899

The average volume for Biocryst Pharmaceuticals has been 916,400 shares per day over the past 30 days. Biocryst Pharmaceuticals has a market cap of $796.3 million and is part of the health care sector and drugs industry. Shares are down 8.22% year-to-date as of the close of trading on Tuesday.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Currently, there are 5 analysts who rate Biocryst Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BCRX - FREE

TheStreet Quant Ratings rates Biocryst Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income. Get the full Biocryst Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing